Soligenix (SNGX) Other financing activities (2010 - 2025)

Soligenix's (SNGX) quarterly Other financing activities came in at $303750.0 in Q4 2025, down 93.16% on a QoQ basis from $4.4 million in Q3 2024.

Soligenix (SNGX) Other financing activities (2010 - 2025) Analysis & Trends

Soligenix (SNGX) has 7 years of Other financing activities data on file, last reported at $303750.0 in Q4 2025.

Quarterly Other financing activities changed N/A year-over-year to $303750.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.7 million (up 6.84% YoY) and the FY2025 annual result came in at $305241.0, down 93.14% from the prior year.
Other financing activities eased to $303750.0 in Q4 2025, from $4.4 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $4.4 million in Q3 2024 to a low of $303750.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Soligenix	6.45 Mn	6.45 Mn	-

Download Data